Short Interest in Synaptogenix, Inc. (NASDAQ:SNPX) Decreases By 66.7%

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 2,400 shares, a drop of 66.7% from the November 30th total of 7,200 shares. Based on an average daily volume of 22,600 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.2% of the company’s shares are sold short.

Synaptogenix Price Performance

SNPX stock traded down $0.13 during mid-day trading on Friday, reaching $3.17. 19,303 shares of the stock traded hands, compared to its average volume of 35,694. The stock’s fifty day moving average is $2.91 and its 200-day moving average is $3.44. Synaptogenix has a 52-week low of $2.32 and a 52-week high of $8.78.

Synaptogenix (NASDAQ:SNPX) last announced its earnings results on Tuesday, November 12th. The company reported ($4.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($2.63).

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.